SCEMBLIX

This brand name is authorized in United States. It is also authorized in Australia, Austria, Canada, Croatia, Estonia, France, Ireland, Israel, Italy, Japan, Lithuania, Romania, Spain, UK.

Active ingredients

The drug SCEMBLIX contains one active pharmaceutical ingredient (API):

1	Asciminib UNII C5U34S9XFV - ASCIMINIB HYDROCHLORIDE
	Asciminib is a potent inhibitor of ABL/BCR::ABL1 tyrosine kinase. Asciminib inhibits the ABL1 kinase activity of the BCR::ABL1 fusion protein by specifically targeting the ABL myristoyl pocket.
	Read more about Asciminib

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
SCEMBLIX Film-coated tablet	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01EA06		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01E Protein kinase inhibitors → L01EA BCR-ABL tyrosine kinase inhibitors
Discover more medicines within L01EA06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
CA	Health Products and Food Branch	02528320, 02528339
EE	Ravimiamet	1888724, 1888735, 1888746, 1888757, 3039948
ES	Centro de información online de medicamentos de la AEMPS	1221670002, 1221670004
FR	Base de données publique des médicaments	65990614, 67826243
IL	מִשְׂרַד הַבְּרִיאוּת	9247, 9248
IT	Agenzia del Farmaco	050185014, 050185026, 050185038, 050185040, 050185053
JP	医薬品医療機器総合機構	4291077F1027, 4291077F2023
LT	Valstybinė vaistų kontrolės tarnyba	1095412, 1095413, 1095414, 1095415
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69170001, W69170002, W69171001, W69171002
US	FDA, National Drug Code	0078-1091, 0078-1098